Lung-molGPA may stratify the prognostic impact of TP53 co-mutation in EGFR-mutant lung adenocarcinoma with brain metastases: a multi-center retrospective analysis
Therapeutic Advances in Medical Oncology · 2026-08 · 18
DOI: 10.1177/17588359261471117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 11.08.2026. Verfasst von Guangchuan Deng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Nan'an District, Chongqing, China. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, natural science foundation of shandong province, Shandong Province Key Discipline of Traditional Chinese Medicine Construction Project.
Abstract (Originalsprache)
Background
The optimal approach to treatment intensification for epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma with brain metastases remains a topic of debate, especially in the context of high-risk molecular features such as TP53 co-mutation. The extent to which baseline clinical risk influences treatment efficacy is yet to be determined.
Objectives
We aim to systematically evaluate the prognostic significance of EGFR/TP53 co-mutations in treatment-naïve patients with lung adenocarcinoma and newly diagnosed brain metastases.
Design
This study enrolled 218 treatment-naïve patients with EGFR-mutant lung adenocarcinoma and brain metastases who received first-line third-generation EGFR-tyrosine kinase inhibitors (TKIs). Treatment effects were evaluated using interaction models stratified by Lung-molGPA scores. Stratification: Group A (Lung-molGPA 1–2) versus Group B (Lung-molGPA 2.5–4).
Methods
Within each group, the influence of TP53 co-mutations on survival was analyzed. Additionally, among patients with TP53 co-mutations, the effects of cranial radiotherapy (CRT) and treatment with either third-generation EGFR-TKIs monotherapy or third-generation EGFR-TKIs combined with chemotherapy on overall survival (OS) were further investigated, taking into account the Lung-molGPA scores.
Results
The Lung-molGPA significantly influenced the prognostic impact of TP53 mutations and the survival benefits of treatment intensification strategies (log-rank test p = 0.044, hazard ratio (HR) = 2.1832, 95% confidence interval (CI): 1.023–4.661). In patients with low Lung-molGPA scores, intensification with CRT did not correlate with a survival advantage (32.2 vs 28.0 m, log-rank test p = 0.5088, HR = 1.417, 95% CI: 0.4768–4.211). Conversely, in patients with high Lung-molGPA scores, both CRT and systemic intensification were associated with improved outcomes (44.0 vs 26.3 m, log-rank test p = 0.0054, HR = 0.3199, 95% CI: 0.1585–0.6456; 20.1 vs 32.3 m, log-rank test p = 0.0074, HR = 2.547, 95% CI: 1.113–5.831).
Conclusion
Baseline clinical risk, as delineated by the Lung-molGPA, serves as a crucial determinant of therapeutic benefit in cases of EGFR-mutant lung adenocarcinoma with cerebral metastases. Implementing risk-adapted treatment intensification strategies could potentially prevent overtreatment in patients classified as low-risk, while simultaneously optimizing clinical outcomes in high-risk cohorts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Nan'an District, Chongqing, China.
- Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan City, China.
- Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan City, Shandong Province, China.
- Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Tianwen Avenue No. 288, Nan'an District, Chongqing 400010, China.
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
ORCID-Profile: Yuan Peng, Zhenxiang Li, Zhenzhou Yang
Förderung
- National Natural Science Foundation of China
- natural science foundation of shandong province
- Shandong Province Key Discipline of Traditional Chinese Medicine Construction Project
- National Key Laboratory for the Integration and Innovation of Classical Formulas and Modern Chinese Medicine
Zitieren
APA
Deng, G., Zhang, Y., Fan, J., Yuanzhu, J., Zhao, C., Lin, J., Peng, Y., Li, Z., & Yang, Z. (2026). Lung-molGPA may stratify the prognostic impact of TP53 co-mutation in EGFR-mutant lung adenocarcinoma with brain metastases: a multi-center retrospective analysis. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261471117
Vancouver
Deng G, Zhang Y, Fan J, Yuanzhu J, Zhao C, Lin J, et al. Lung-molGPA may stratify the prognostic impact of TP53 co-mutation in EGFR-mutant lung adenocarcinoma with brain metastases: a multi-center retrospective analysis. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261471117
BibTeX
@article{Deng2026,
author = {Deng, Guangchuan and Zhang, Yanxin and Fan, Jing and Yuanzhu, Jiang and Zhao, Chenran and Lin, Jiamao and Peng, Yuan and Li, Zhenxiang and Yang, Zhenzhou},
title = {Lung-molGPA may stratify the prognostic impact of TP53 co-mutation in EGFR-mutant lung adenocarcinoma with brain metastases: a multi-center retrospective analysis},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261471117}
}
EUVIMED